Mozhgan Dorkhan has been appointed Chief Scientific Officer of Smartfish AS with effect from 01.09.2019.
“We are excited to announce Mozhgan as our new Chief Scientific Officer. Mozhgan has extensive experience in clinical research, medical education and medical affairs within the pharmaceutical industry. Together with her strong drive and positive and agile attitude, we are convinced Mozhgan is the perfect fit for Smartfish. I look forward to welcome Mozhgan as a part of the management team where she will play a key role in shaping Smartfish future” says Geir Harstad, CEO of Smartfish.
Mozhgan comes from a position as Senior Global Medical Director at Novo Nordisk AS, and has previously worked as Medical Advisor at Eli Lilly. Mozhgan also brings with her experience as a Specialist Physician at Skåne University Hospital, Malmö Sweden. She holds a PhD and M.D from Lund University, Sweden where she is Associate Professor. Mozhgan is also author or co-author of close to 30 publication.
“I look forward to use my experience to further develop Smartfish’s Scientific strategy and take on new challenges in a constantly evolving company” states Mozhgan. “Smartfish is a company in rapid growth, and I am excited to be a part of its future”
Mozhgan will succeed Maria Beck who has decided to focus on her consultancy business and board positions. Maria will continue to support Smartfish as a consultant.
Following the appointment, Smartfish’s management group will consist of the following five executives:
- Chief Executive Officer: Geir Harstad
- Chief Financial Officer: Kamilla Hassander
- VP Sales & Marketing: Jens Nordahl
- Chief Operating Officer: Christel Kanli
- Chief Scientific Officer: Mozhgan Dorkhan
“With this last appointment, Smartfish has established a management team ready to leverage on the growth opportunities going forward” says Harstad.